How the New PCOS Name PMOS Aims to Break Decades of Stigma Surrounding Women's Health
Polycystic Ovary Syndrome is getting a new name — PMOS — and researchers say the change is about far more than terminology. After more than a decade of work, experts behind the rename hope it will dismantle long-standing myths and validate millions of patients who have felt dismissed.
What Does PMOS Stand for and Why Is PCOS Being Renamed?
PMOS stands for polyendocrine metabolic ovarian syndrome, the new official name for what has long been called Polycystic Ovary Syndrome (PCOS). The change was announced after a global consensus project led by researchers at Monash University and Oulu University, and was published in The Lancet.
The rename was driven by a simple problem: the old name focused on ovarian “cysts” and obscured the fact that the disorder affects hormonal, metabolic, reproductive and psychological health. Researchers argued that “polycystic ovary syndrome” misled patients, clinicians and the public into treating the condition as a minor reproductive issue rather than the systemic endocrine disorder it is.
Professor Helena Teede, director of Monash University’s Monash Centre for Health Research & Implementation and an endocrinologist at Monash Health, led the effort alongside 56 patient and professional organizations. “The agreed principles of the new name included patient benefit, scientific accuracy, ease of communication, avoidance of stigma, cultural appropriateness and accompanying implementation,” she said, according to the Endocrine Society.
Teede called the rename a turning point. “This change was driven with and for those affected by the condition and we are proud to have arrived at a new name that finally accurately reflects the complexity of the condition. Make no mistake, this is a landmark moment that will lead to desperately needed worldwide advancements in clinical practice and research.”
The new terminology centers three core features of the disorder: its endocrine impact, its metabolic effects and its ovarian component. Researchers say that framing better captures what patients actually experience, from insulin resistance and elevated androgens to irregular periods, acne, weight changes and infertility. The shift also aligns medical language with current science, which has long recognized that the condition extends well beyond the ovaries.
How Does the PMOS Name Change Address PCOS Stigma?
Stigma reduction was identified as a primary goal of the renaming process, and experts say the old PCOS label fueled misunderstanding for decades. Because the name centered on “cysts,” many patients were told — or assumed — they had a minor reproductive problem, when in reality the disorder is a complex hormonal and metabolic condition.
Dr. Alla Vash-Margita, associate professor of obstetrics, gynecology and reproductive sciences at Yale University and division chief for pediatric adolescent gynecology at the Yale School of Medicine, told CNN the old name distorted public understanding. “By calling this condition polycystic ovary, we’re missing the big picture,” she said. “There was a lot of stigma and myth related to this name. People thought they have large cysts, which they do not have.”
Symptoms such as weight gain, acne, irregular periods, infertility and excess hair growth have often been treated as personal shortcomings rather than recognized medical signs. Researchers behind the PMOS rename say that misperception led to delayed diagnoses, dismissive clinical encounters and a sense among patients that their experiences weren’t taken seriously.
For more information: PCOS Has Been Renamed: Everything to Know About the New Name PMOS and Why It Was Changed
Cultural considerations also shaped the new name. Professor Terhi Piltonen, an international co-lead from Oulu University and Oulu University Hospital, said researchers were careful to avoid reproductive terminology that could compound stigma in some parts of the world. “It was essential that the new name was scientifically correct but also considered across diverse cultural contexts to avoid certain reproductive terms that could heighten stigma and be harmful for women in some countries,” Piltonen said. “This made a culturally and internationally informed consultation critical to getting it right.”
Lorna Berry, an Australian woman who has PMOS and participated in the study, framed the change as generational. “This is about accountability and progress,” she said. “It is about my daughters, their daughters and the countless women yet to be born. We deserve clarity, understanding and equitable healthcare from the very beginning.”
By repositioning the disorder as a systemic endocrine and metabolic condition, advocates hope the new language will push earlier diagnoses, improve clinical care and help patients feel believed by both providers and the broader public.
Who Led the PMOS Research and How Was the New Name Chosen?
The PMOS name was the result of a large, international consensus process that combined surveys, expert panels and patient feedback over multiple stages. According to the study, the project involved 56 academic, clinical and patient advocacy organizations and gathered responses from 14,360 people, including individuals diagnosed with the condition along with multidisciplinary healthcare professionals from different global regions.
Researchers conducted iterative global surveys to understand how patients and clinicians perceived the existing PCOS label and what they believed a revised name should communicate. They evaluated factors such as scientific accuracy, clarity, cultural appropriateness, feasibility and stigma reduction. The team also used modified Delphi methods — a structured process often used in medical research to build expert consensus through repeated rounds of anonymous feedback and voting.
In addition, the study included nominal group workshops, where experts and patient representatives discussed and refined naming options together in guided sessions. Marketing and implementation analyses were performed to determine whether a new name could realistically be adopted across healthcare systems, medical education, research institutions and public communication.
Through that multistep process, researchers reached consensus on “Polyendocrine Metabolic Ovarian Syndrome.” The team concluded the term more accurately reflects the condition’s endocrine, metabolic and reproductive features while helping reduce misunderstanding for patients who have long felt their diagnosis was minimized.
Teede emphasized that the rename is meant to translate into real-world change, calling it a step toward “desperately needed worldwide advancements in clinical practice and research.”
Implementation will now fall to medical bodies, educators and health systems worldwide, which will need to update guidelines, training materials and patient-facing communications to reflect the PMOS terminology.
This article was created by content specialists using various tools, including AI.
